Can cervical cancer patients stop immunotherapy early? new study investigates

NCT ID NCT07645625

Recruiting now Disease control Sponsor: University Medical Center Groningen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times

Summary

This study follows 261 people with persistent, recurrent, or metastatic cervical cancer who are taking pembrolizumab (Keytruda) with or without bevacizumab (Avastin). Some participants may choose to stop pembrolizumab early if their tumor shrinks or disappears, while others continue standard treatment. Researchers will track how long the cancer stays under control and compare results to previous trials, aiming to see if early discontinuation is a safe option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pembrolizumab (Keytruda) with or without bevacizumab (Avastin)
What this could lead to: If successful, this could show that stopping pembrolizumab early is safe and effective for some patients with advanced cervical cancer, potentially reducing treatment burden.
What could go wrong: This is an observational registry, not a controlled trial, so results may be less definitive. Early discontinuation might lead to higher relapse risk, and findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CERVICAL CANCER

Contacts and locations

Locations

Amsterdam UMC
NOT_YET_RECRUITING

Amsterdam, Netherlands
Antoni van Leeuwenhoek Ziekenhuis
NOT_YET_RECRUITING

Amsterdam, Netherlands
Catharina Ziekenhuis
RECRUITING

Eindhoven, Netherlands
Erasmus MC
NOT_YET_RECRUITING

Rotterdam, Netherlands
Isala Klinieken
NOT_YET_RECRUITING

Zwolle, Netherlands
LUMC
RECRUITING

Leiden, Netherlands
Maastricht UMC
NOT_YET_RECRUITING

Maastricht, Netherlands
Medisch Spectrum Twente
NOT_YET_RECRUITING

Enschede, Netherlands
Radboud UMC
NOT_YET_RECRUITING

Nijmegen, Netherlands
UMC Utrecht
NOT_YET_RECRUITING

Utrecht, Netherlands
University Mecdical Center Groningen
RECRUITING

Groningen, 9713 GZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.